Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement

This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.

This document summarises the Chief Medical Officer's consideration of Alexion Pharmaceuticals Australasia Pty Ltd's application to include asfotase alfa (Strensiq®) on the Life Saving Drugs Program for the treatment of peri-natal and infantile onset hypophosphatasia.

Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement

About this resource

Publication date:
Publication type:
Report
Audience:
General public
Language:
English

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.